Hutch News

Hutch News

Stories tagged 'Philip D Greenberg'

Hutch science featured at world's premier cancer immunotherapy meeting

Researchers honored at SITC 2018 for work on immune-based treatments for leukemia, ovarian cancer, skin cancer

Nov. 14, 2018 | By Susan Keown / Fred Hutch News Service

Fred Hutch's Drs. Philip Greenberg, Kristin Anderson and Kelly Paulson were honored Nov. 10 at the annual meeting of the Society for Immunotherapy of Cancer in Washington, D.C.

View story >


5 questions with a cancer immunotherapy expert

Dr. Phil Greenberg to receive high honor for his contributions to the field

Nov. 7, 2018 | By Susan Keown / Fred Hutch News Service

Immune-harnessing treatments are revolutionizing cancer care. Where is the immunotherapy field now, and what's next? Fred Hutch science writer Susan Keown asked someone who would know: Dr. Phil Greenberg.

View story >


3 big new leukemia research projects advance cutting-edge cell therapies, stem cell transplant

$20M renewal of 4-decade-long federal grant to Hutch scientists

May 31, 2018 | By Susan Keown / Fred Hutch News Service

The National Cancer Institute has awarded Hutch with five years and nearly $20 million in funding for research to develop better therapies for people with blood cancers. The award is the latest renewal of a grant that has been funded continuously for more than 40 years.

View story >


Tinkering with T cells

How researchers are tweaking engineered immune cells’ cancer-targeting receptors — and why it matters

May 15, 2018 | By Susan Keown / Fred Hutch News Service

These immune cells are the cornerstone of emerging cancer therapies. And their unimaginably tiny, cancer-targeting molecular weapons — their receptors — are the focus of intense scientific tinkering.

View story >


Immunotherapy strategy for ovarian cancer aims to rewire a ‘kill switch’ to ramp-up signal

T cells bearing a new engineered protein boost immunotherapy’s effectiveness in laboratory models of AML, ovarian, pancreatic cancers

April 16, 2018 | By Rachel Tompa / Fred Hutch News Service

In an effort to improve the efficacy of immunotherapy for solid tumors, Fred Hutch researchers have engineered a new type of protein that can rewire a 'kill switch' to stimulate T cells' activity instead.

View story >


How does leukemia escape from immunotherapy?

New tech enables deep dive into mysterious results, sets stage for future improvements

April 16, 2018 | By Susan Keown / Fred Hutch News Service

“We don’t stop asking what we can do better”: Fred Hutch researchers delve into failures to learn how to improve an experimental cancer immunotherapy.

View story >



(RSS feeds are best viewed in browsers other than Chrome)

Editor's Picks

GIVE NOW &
SAVE LIVES

Support our quest for cures

Story Archive


Publications

Magazine Archive
Back issues of Hutch Magazine

Financial Reporting
Fiscal highlights & Annual Reports

Science Spotlight
Monthly review of Center-authored papers



Fred Hutch News

        Get updates via email.